Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 10, 2011, Pages 4123-4128

  Cao, Dian J ^a   Wang, Zhao V ^a   Battiprolu, Pavan K ^a   Jiang, Nan ^a   Morales, Cyndi R ^a   Kong, Yongli ^a   Rothermel, Beverly A ^a   Gillette, Thomas G ^a   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PHENYLEPHRINE; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL ACTIVATION; CELL GROWTH; CELL STRESS; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ACETYLATION; ANIMALS; AUTOPHAGY; CARDIOMEGALY; HISTONE DEACETYLASE INHIBITORS; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MUS;

EID: 79952775153     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015081108     Document Type: Article

References (48)

1. Lloyd-Jones D, et al. (2010) Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 121:e46-e215.
2. Kook H, et al. (2003) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112:863-871. (Pubitemid 38063744)
3. Kong Y, et al. (2006) Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113:2579-2588. (Pubitemid 43948006)
4. Kee HJ, et al. (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113:51-59. (Pubitemid 43958488)
5. Berry JM, Cao DJ, Rothermel BA, Hill JA (2008) Histone deacetylase inhibition in the treatment of heart disease. Expert Opin Drug Saf 7:53-67. (Pubitemid 351222963)
6. Granger A, et al. (2008) Histone deacetylase inhibition reduces myocardial ischemiareperfusion injury in mice. FASEB J 22:3549-3560.
7. Levine B, Klionsky DJ (2004) Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Dev Cell 6:463-477. (Pubitemid 38456176)
8. Klionsky DJ (2007) Autophagy: From phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8:931-937.
9. Mizushima N (2007) Autophagy: Process and function. Genes Dev 21:2861-2873.
10. Kundu M, Thompson CB (2008) Autophagy: Basic principles and relevance to disease. Annu Rev Pathol 3:427-455. (Pubitemid 351488288)
11. Kim I, Rodriguez-Enriquez S, Lemasters JJ (2007) Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 462:245-253. (Pubitemid 46876640)
12. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132:27-42.
13. Zhu H, et al. (2007) Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 117:1782-1793. (Pubitemid 47036312)
14. Nakai A, et al. (2007) The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13:619-624. (Pubitemid 46828485)
15. Martinet W, Knaapen MW, Kockx MM, De Meyer GR (2007) Autophagy in cardiovascular disease. Trends Mol Med 13:482-491. (Pubitemid 350086977)
16. Rothermel BA, Hill JA (2008) Autophagy in load-induced heart disease. Circ Res 103:1363-1369.
17. Wang ZV, Rothermel BA, Hill JA (2010) Autophagy in hypertensive heart disease. J Biol Chem 285:8509-8514.
18. Hill JA, et al. (2000) Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101:2863-2869. (Pubitemid 30396019)
19. Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358:1370-1380.
20. Marks PA (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19:1049-1066.
21. Amaravadi RK, et al. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117:326-336. (Pubitemid 46203961)
22. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10:32-42.
23. Göttlicher M, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978. (Pubitemid 34062289)
24. Kaneda R, et al. (2005) Genome-wide screening for target regions of histone deacetylases in cardiomyocytes. Circ Res 97:210-218. (Pubitemid 41105446)
25. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. (Pubitemid 44348499)
26. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468.
27. Trivedi CM, et al. (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 13:324-331. (Pubitemid 46376684)
28. Lagger G, et al. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672-2681. (Pubitemid 34619383)
29. Montgomery RL, et al. (2007) Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21:1790-1802. (Pubitemid 47076478)
30. Zimmermann S, et al. (2007) Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 67:9047-9054. (Pubitemid 47535889)
31. Guan JS, et al. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:55-60.
32. Chang S, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467-8476. (Pubitemid 39245069)
33. McKinsey TA, Zhang CL, Olson EN (2000) Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA 97:14400-14405.
34. Zhang CL, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479-488. (Pubitemid 35232291)
35. Lahm A, et al. (2007) Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 104:17335-17340. (Pubitemid 350219843)
36. Guardiola AR, Yao TP (2002) Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277:3350-3356. (Pubitemid 34953202)
37. Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101:18030-18035. (Pubitemid 40054069)
38. Carew JS, et al. (2010) Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 14:2448-2459.
39. Carew JS, et al. (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110:313-322. (Pubitemid 47026849)
40. Kehat I, Molkentin JD (2010) Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122:2727-2735.
41. Depre C, et al. (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114:1821-1828. (Pubitemid 44673357)
42. Willis MS, Schisler JC, Portbury AL, Patterson C (2009) Build it up-Tear it down: Protein quality control in the cardiac sarcomere. Cardiovasc Res 81:439-448.
43. Sengupta A, Molkentin JD, Yutzey KE (2009) FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 284:28319-28331.
44. Meiners S, et al. (2008) Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51:302-308. (Pubitemid 351159943)
45. Stansfield WE, et al. (2008) Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 294:H645-H650. (Pubitemid 351253275)
46. Nishino I, et al. (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406:906-910. (Pubitemid 30664268)
47. Masiero E, et al. (2009) Autophagy is required to maintain muscle mass. Cell Metab 10:507-515.
48. Ni YG, et al. (2007) FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 104:20517-20522.